Posted by Michael Wonder on 27 Jun 2025
Achieve Life Sciences announces submission of NDA to FDA for cytisinicline as a treatment of nicotine dependence for smoking cessation
26 June 2025 - More than 2,000 clinical trial participants contributed to the body of evidence submitted in the new drug application demonstrating cytisinicline’s efficacy, safety, and tolerability profile.
Achieve Life Sciences today announced the submission of a new drug application to the US FDA for cytisinicline as a treatment of nicotine dependence for smoking cessation in adults.
